Dusa Gets FDA Warning On Ad For Actinic Keratoses Therapy
This article was originally published in The Pink Sheet Daily
Executive SummaryDDMAC cites firm for broadening the indication, minimizing the risks and overstating the effectiveness of its photosensitizing agent Levulan.
You may also be interested in...
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.